Clinical potential and challenges of spatially profiling tumor-infiltrating lymphocytes in early-stage breast cancer.

Digitally automated spatial profiling of immune-tumor cell interactions using multispectral immunofluorescence holds promise as a biomarker to predict outcomes in early-stage breast cancer, but prospective validation and harmonization with existing biomarkers is necessary before clinical adoption.